Jeff Jones
Stock Analyst at Oppenheimer
(1.99)
# 3,098
Out of 5,124 analysts
96
Total ratings
29.89%
Success rate
-0.94%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Outperform | $67 → $120 | $77.81 | +54.22% | 7 | Dec 9, 2025 | |
| PTHS Pelthos Therapeutics | Reiterates: Outperform | $50 → $57 | $31.00 | +83.87% | 2 | Nov 14, 2025 | |
| VTYX Ventyx Biosciences | Maintains: Outperform | $9 → $14 | $9.03 | +55.04% | 11 | Oct 27, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $1.65 | +1,415.15% | 9 | Aug 27, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $56 → $53 | $8.14 | +551.11% | 10 | Aug 6, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $20.12 | +118.69% | 3 | Jun 24, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $9.76 | +156.15% | 3 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $5.24 | +224.43% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $7.70 | +120.78% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $34.60 | +148.55% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $4.00 | +350.00% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.88 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $2.75 | +481.82% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.22 | +3,588.52% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $14.85 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.14 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.84 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.25 | +1,100.00% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,875 | $3.31 | +56,546.53% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $4.77 | +22,960.80% | 2 | Nov 17, 2022 |
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $67 → $120
Current: $77.81
Upside: +54.22%
Pelthos Therapeutics
Nov 14, 2025
Reiterates: Outperform
Price Target: $50 → $57
Current: $31.00
Upside: +83.87%
Ventyx Biosciences
Oct 27, 2025
Maintains: Outperform
Price Target: $9 → $14
Current: $9.03
Upside: +55.04%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $1.65
Upside: +1,415.15%
Corbus Pharmaceuticals Holdings
Aug 6, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $8.14
Upside: +551.11%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $20.12
Upside: +118.69%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $9.76
Upside: +156.15%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $5.24
Upside: +224.43%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $7.70
Upside: +120.78%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $34.60
Upside: +148.55%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $4.00
Upside: +350.00%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $2.88
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $2.75
Upside: +481.82%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.22
Upside: +3,588.52%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $14.85
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.14
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $5.84
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.25
Upside: +1,100.00%
Mar 24, 2023
Reiterates: Outperform
Price Target: $1,875
Current: $3.31
Upside: +56,546.53%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $4.77
Upside: +22,960.80%